Brain natriuretic peptide for prevention of contrast-inducednephropathy: a meta-analysis of randomized controlled trials

Wei, Xuebiao; Jiang, Lei; Liu, Xinrong; Yu, Danqing; Tan, Ning; Chen, Jiyan; Zhou, Yingling; He, Pengcheng; Liu, Yuanhui

doi:10.1007/s00228-016-2135-9

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results presented a statistically significant reduction of the occurrence of CIN and the change of SCr levels by pharmacological intervention from RCTs. The previous meta-analysis made by Wei et al (2016b) summarized the incidence of CIN after intervention with BNP from five RCTs with 1,441 patients but was limited to analysis the SCr level change. Past meta-analysis lack a comparison study in treatment effect and intervention dose between BNP and nicorandil for preventing CIN incidence.…”

Section: Discussionmentioning

confidence: 99%

“…These years, prostaglandin analogues and BNP analogues are applied to prevent the CIN in the PCI and CAG. Some RCTs showed BNP and nicorandil interventions could reduce the incidence of CIN and SCr levels in the PCI and CAG ( Wei et al, 2016a ; Pranata et al, 2020 ). However, there was no study evaluating and comparing the efficacy of BNP and nicorandil on preventing CIN.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis

Mei

Luo

Chen

et al. 2022

PeerJ

View full text Add to dashboard Cite

This study aimed to conduct a network meta-analysis (NMA) to compare the efficacy of brain natriuretic peptide (BNP) vs nicorandil for preventing contrast-induced nephropathy (CIN). Databases of Pubmed, Cochrane, Embase, Web of Science were searched by keywords for eligible studies of randomized controlled trials investigating different agents (BNP, nicorandil, nitroglycerin, intravenous saline) for preventing CIN. The outcomes included a change in serum creatinine level at 48 h and the incidence of CIN after percutaneous coronary intervention (PCI) or coronary angiography (CAG). A total of 13 studies with 3,462 patients were included. Compared with intravenous saline alone, except for nitroglycerin (odds ratio [OR]: 1.02, 95% CI [0.36–2.88]), the other drugs significantly reduced the CIN incidence with OR of 0.35 (95% CI [0.24–0.51]) for BNP, 0.52 (0.29, 0.94) for usual-dose nicorandil, 0.28 (0.19, 0.43) for double-dose nicorandil. BNP and double-dose nicorandil significantly decreased the change of serum creatinine (SCr) levels with mean difference (MD) of −6.98, (−10.01, −3.95) for BNP, −8.78, (−11.63, −5.93) for double-dose nicorandil. No significant differences were observed in the change of SCr levels for nitroglycerin (−4.97, [−11.46, 1.52]) and usual-dose nicorandil (−2.32, [−5.52, 0.89]) compared with intravenous saline alone. For double-dose nicorandil, the CIN incidence and the change of SCr level in group of 4–5 days treatment course were more than group of less than or equal to 24 h treatment course (OR of 1.48, [0.63–3.46] and MD of 2.48, [−1.96, 6.91]). In conclusion, BNP and double-dose nicorandil can have effects on preventing the incidence of CIN and double-dose nicorandil performed better than BNP. In double-dose nicorandil groups, a course of less than or equal to 24 h before and after procedure performed with better efficacy than a course of 4–5 days.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%